ONCOLOGY: March 2010 Volume 24 Number 3 Supplement 2

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

How Can Oncology Staffing Shortages Be Remedied?

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Ariana Pelosci

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Roman Fabbricatore

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

FDA Clears IND Application for Novel IL-2 Agent in Advanced NSCLC

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Related Content

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

ILKN421H plus pembrolizumab previously showed antitumor activity among patients with frontline non–small cell lung cancer in a phase 1 trial.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

How Can Oncology Staffing Shortages Be Remedied?

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Ariana Pelosci

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Manali Patel, MD, MPH, MS, FASCO, discusses current gaps, projected needs, and actionable strategies for the US hematology and medical oncology workforce.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Roman Fabbricatore

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Considering historical trends of underpowered data in NET surgical studies, CUTNETs established a collaboration of surgical teams to better power research.